Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648138 | 0.93 | FNTA (0.52) | — | |
| Lithium SCHEMBL7871086 | 0.92 | FNTA (0.51) | — | |
| Lithium Ion SCHEMBL7869147 | 0.91 | — | — | |
| Lithium Ion SCHEMBL7869136 | 0.90 | — | — | |
| Lithium Ion SCHEMBL7862372 | 0.90 | — | — | |
| SCHEMBL7869153 | 0.83 | — | — | |
| SCHEMBL7869150 | 0.83 | — | — | |
| Lithium Ion SCHEMBL7867392 | 0.83 | — | — | |
| Lithium Ion SCHEMBL7870231 | 0.83 | — | — | |
| Lithium Ion SCHEMBL7870172 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |